GHIT

Japan’s Global Health Innovative Technology Fund announced $21 million in product development investments on Wednesday.

More than two-thirds of the awards will help advance six ongoing projects, while the rest fund four new investments: a leishmaniasis drug from Takeda and the Drugs for Neglected Diseases initiative; a malaria therapy from Eisai, the Medicines for Malaria Venture and the University of Dundee; a tuberculosis drug from Daiichi Sankyo RD Novare and the TB Alliance; and a…

The Pediatric Praziquantel Consortium announced new funding last month from Japan’s Global Health Innovative Technology (GHIT) Fund and the European & Developing Countries Clinical Trials Partnership.

The separate awards—worth a combined $9.3 million—will fund the ADOPT program, dedicated to “wide acceptance and equitable access” for a child-friendly dispersible tablet formulation of schistosomiasis drug praziquantel.

With backers including Astellas, Farmanguinhos and Merck…

Japan’s nonprofit Global Health Innovative Technology Fund (GHIT Fund) announced $2.2 million in drug development investments on Tuesday.

Three of the four awards support new projects for Chagas disease and malaria. The remaining award goes toward an ongoing drug discovery project between Takeda and Geneva-based Medicines for Malaria Venture.

GHIT Fund’s portfolio now includes 53 ongoing projects with $217 million invested so far, according to the press release.

Mentions:

Japan’s nonprofit Global Health Innovative Technology Fund (GHIT Fund) on Monday announced $13 million in drug and diagnostic investments.

Three of the seven awards will support new projects for malaria drug development and tests for schistosomiasis and Buruli ulcers. The remaining four will go toward ongoing projects to develop drugs for leishmaniasis, Chagas and soil-transmitted helminths and a rapid diagnostic for malaria.

GHIT Fund’s portfolio now includes 50 ongoing…

Japan’s nonprofit Global Health Innovative Technology Fund (GHIT Fund) launched a new RFP this week calling for novel drugs, diagnostics and vaccines for malaria, tuberculosis and neglected tropical diseases to “address health needs in the developing world or fill a gap in global health technologies for infectious diseases.”

Applications are due July 29 and full proposals August 17.

The Lancet Infectious Diseases published Phase 1a/b results last week showing that the novel anti-malarial SJ733 displayed a favorable pharmacokinetic, tolerability and safety profile in study participants. The results support further development of the P. falciparum ATP4 inhibitor as a fast-acting component of combination therapy.

Earlier this month, Japan’s Global Health Innovative Technology Fund (GHIT) announced a $5.1 million award to Eisai and its academic partners to develop the…

Mentions:

Japan’s Global Health Innovative Technology Fund announced yesterday $30 million in new product development investments.

More than two-thirds of the awards will go toward advancing six ongoing projects and the rest to fund five new investments in malaria, leishmaniasis and mycetoma, according to the press release.

Japan’s Global Health Innovative Technology Fund awarded $5.9 million in funding this week to eight projects seeking to develop diagnostics, drugs and vaccines for Chagas disease, leishmaniasis, malaria and tuberculosis (TB).

Industry recipients included Takeda, with three malaria awards and one TB drug award, and Mitsubishi Tanabe Pharma Company, with one Chagas and leishmaniasis drug award.

The Ohio State University (OSU) College of Medicine announced last week that Britain’s Wellcome Trust has given it $650,000 to test a visceral leishmaniasis (VL) vaccine in dogs to reduce their risk as carriers.

In March, Japan’s Global Health Innovative Technology (GHIT) Fund also awarded the college $3.6 million to support manufacturing of clinical-grade materials in preparation for human VL vaccine trials.

Japan’s Global Health Innovative Technology Fund (GHIT) announced last week that it has appointed BMS executive Catherine Ohura as its new CEO and executive director, effective April 1. Ohura replaces founding CEO BT Slingsby, who announced last September that he would be stepping down at the end of Japan’s 2018 fiscal year (March 2019).

Last week, GHIT also announced $25.8 million in new product development funding for malaria, TB, dengue, leishmaniasis and schistosomiasis. The…